United Kingdom

People: Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

22 Jul 2019
Change (% chg)

$0.49 (+4.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kaye, Edward 

Dr. Edward M. Kaye, M.D., is Independent Director of the Company. Dr. Kaye currently serves as the Chief Executive Officer and a member of the Board of Sarepta Terapeutics, Inc., a biotechnology company. Prior to this, Dr. Kaye served as Interim Chief Executive Officer of Sarepta from March 31, 2015 to September 19, 2016 and as the SVP, Chief Medical Officer since 2011. Dr. Kaye was Group Vice President of Clinical Development at Genzyme Corporation, a biotechnology company, from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Dr. Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He received his Pediatric training at Loyola University Hospital, Child Neurology training at Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at Bedford VA Hospital, Boston University.

Basic Compensation

Total Annual Compensation, USD 7,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 259,781
Fiscal Year Total, USD 267,281

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leonard Patrick Gage


Robert Blum


Ching Jaw


Fady Malik


David Cragg


Robert Wong

As Of  31 Dec 2017